• Annual Report 2019

    Online Version

To our Shareholders

Sustainability is a term that shapes many current debates like perhaps no other. The medium- and long-term consequences of actions, whether those of individuals or organizations, are being examined ever more closely. Short-term effects and success are becoming less important. More importance is being given to the long-term impact of decisions and acts – on people, on the economy, and on the planet.

Read more

Management Board

Pictured left to right:   DR. ERNST WASTLER · CEO Fresenius Vamed       DR. FRANCESCO DE MEO · CEO Fresenius Helios       MATS HENRIKSSON · CEO Fresenius Kabi (left the company as of March 16, 2021)      STEPHAN STURM · Chairman of the Management Board (left the company as of September 30, 2022)      RACHEL EMPEY · Chief Financial Officer (left the company as of August 31, 2022)      DR. JÜRGEN GÖTZ · Chief Legal and Compliance Officer, and Labor Relations Director (left the company as of June 30, 2020)      
RICE POWELL · CEO Fresenius Medical Care (left the company as of September 30, 2022)

Financial Highlights

Sales 1


+6% 2

FY/18: €33,009 m




FY/18: €0.80


4,599 m

-2% 2

FY/18: €4,547 m



Dec. 31, 2018: 276,750

Net Income 1

1,915 m

0% 2

FY/18: €1,872 m

Earnings per Share 1


0% 2

FY/18: €3.37

1 On a comparable basis
2 In constant currency

Fresenius Strategy

  • Fresenius Medical Care

    Fresenius Medical Care achieved solid growth in 2019. We are working successfully to offer even more patients even better and more individual treatment options. The integration of the NxStage product line has led to record growth in the number of home dialysis patients.

  • Fresenius Kabi

    In 2019, the excellent growth in the emerging markets was particularly noteworthy, partially offsetting the somewhat softer performance in North America. With organic sales growth of 4% and EBIT growth in constant currency of 3%, we achieved our 2019 financial outlook.

  • Fresenius Helios

    We achieved our sales and earnings outlook. The investments made in connection with regulatory requirements in Germany are showing positive effects. The business in Spain continues to grow dynamically. We have strengthened our presence in Latin America.

  • Fresenius Vamed

    In 2019, we recorded excellent sales development of 31% and organic sales growth of 16%. The integration of post-acute care facilities in Germany has been successfully completed and further strengthens our service business. A very strong order book secures future growth in the project business.

Group Management Report

In 2019, Fresenius made significant investments in all business segments to lay the foundation for future growth. We achieved our targets for both Group sales and earnings in 2019.

Group Management Report

Group Non-Financial Report

We are committed to responsible management and ethical business principles as an integral part of the Fresenius corporate culture.

Group Non-Financial Report